For instance, clinically approved antiangiogenic therapies for metastatic colorectal cancer include bevacizumab (an antibody against the VEGF-A ligand), aflibercept (a recombinant protein trap of the VEGF-A, VEGF-B and PlGF ligands) and ramucirumab (an antibody to VEGF receptor-2, VEGFR2) that are given with chemotherapy, as well as regorafenib monotherapy (a VEGFR2 tyrosine kinase inhibitor (TKI))1. This evidence concerns the gene VEGFA and metastatic colorectal cancer.